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Abstract	
		 Malaria	is	a	devastating	disease	that	continues	to	affect	millions	of	people	worldwide	every	year.	Specifically,	Plasmodium	falciparum	is	the	most	common	human	malaria	parasite,	particularly	in	sub-Saharan	Africa.	P.	falciparum	causes	the	most	malignant	and	debilitating	symptoms	with	the	highest	mortality	and	complication	rates.	Even	with	the	worldwide	efforts	of	many	researchers	and	organizations,	the	road	to	discovering	a	vaccine	has	been	difficult	and	challenging.	Due	do	to	the	improvements	in	in	
vitro	liver	stage	assays	as	well	as	rodent	models	of	mammalian	malaria,	pre-erythrocytic	stages	of	malaria	have	become	a	more	accessible	target	for	experimental	studies.	These	vaccine	candidates	target	Plasmodium	sporozoites	in	the	liver	and	liver	stages	to	prevent	development	to	the	blood-stage	forms,	which	is	responsible	for	the	debilitating	symptoms	of	the	disease.	Scanning	electron	microscopy	has	been	used	for	decades	to	provide	insight	on	the	morphology	and	topography	of	specimens,	which	cannot	be	seen	through	a	light	microscope.	The	purpose	of	this	study	was	to	analyze	the	morphology	of	sporozoites	with	some	target	antibodies.	Sporozoites	have	previously	shown	uncharacterized	appearances	and	development	in	an	immunofluorescent	stain	at	different	concentrations	of	particular	antibodies.	With	this	further	understanding	on	the	morphological	impact	few	of	the	target	antibodies	have	on	sporozoites	through	scanning	electron	microscopy,	further	grasp	can	be	acquired.
	 	1	
	
	
	
Chapter	One		
Introduction	
		 Malaria	is	a	life-threatening	disease	affecting	millions	of	people	world-	wide.	In	2015	alone,	there	were	an	estimated	214	million	cases	of	malaria	with	over	438,000	deaths	(WHO,	2016).	Those	who	reside	in	the	poorest	countries	are	especially	vulnerable,	primarily	children	under	the	age	of	5.	Not	only	does	this	debilitating	disease	have	an	impact	on	the	population	health,	the	economic	consequences	can	also	be	devastating.	In	African	countries	alone,	malaria	drains	as	much	as	2%	of	the	Gross	Domestic	Product	(Mota	&	Rodriguez,	2002).	In	the	past	15	years	the	malaria	mortality	rate	has	dropped	over	45%	predominantly	due	to	widespread	funding	for	malaria	control	interventions	such	as	long-term	insecticidal	nets,	access	to	artemisinin	combination	therapy	(ACT)	and	indoor	residual	spraying	programs	(CDC,	2016).	While	there	has	been	an	overall	global	reduction	in	disease	burden,	the	continued	spread	of	drug	and	insecticide	resistance	makes	eliminating	malaria	both	crucial	and	worthwhile	(Stresman,	Cameron,	&	Drakeley,	2017).			 Malaria	is	caused	by	protozoan	parasites	belonging	to	the	genus	Plasmodium	(WHO,	2016).	There	are	five	species	that	cause	infection	in	humans,	Plasmodium	falciparum,	
Plasmodium	vivax,	Plasmodium	ovale,	Plasmodium	malariae	and	Plasmodium	knowlesi.	P.	
falciparum	(P.f.)	is	responsible	for	the	majority	of	malaria	deaths	globally	and	is	the	most	prevalent	species	in	Sub-Saharan	Africa	(CDC,	2016).	Aside	from	P.	falciparum,	P.	vivax	is	
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the	most	widely	distributed	parasite	outside	of	Africa	and	is	primarily	located	in	Southeast	Asia	and	Latin	America	(CDC,	2016).		
	
Life	Cycle	The	malaria	parasite	is	known	to	have	a	complex	life	cycle.	The	disease	is	transmitted	once	a	malaria-infected	Anopheles	mosquito	blood	feeds	on	a	human	whereupon	~100	sporozoites	are	injected	into	the	mammalian	circulation	and	travel	through	the	blood	stream	via	gliding	motility	(Stewart	&	Vanderberg,	1988).	Sporozoites	have	evolved	to	be	well-adapted	to	its	host	as	infection	can	occur	with	as	little	as	10	sporozoites	(Ungureanu	et	al.,	1976).	The	sporozoites	travel	through	the	bloodstream	to	quickly	reach	the	liver	of	the	mammalian	host,	and	recognize	the	liver	via	a	process	thought	to	be	mediated	by	circumsporozoite	(CS)	protein	(Mota	&	Rodriguez,	2002).	Once	the	sporozoites	arrive	in	the	liver,	they	infect	hepatocytes,	and	within	7-14	days	they	develop	into	schizonts.	When	the	schizonts	are	fully	matured,	the	hepatocyte	ruptures,	releasing	thousands	of	meorozoites	into	the	blood	stage.	After	this	stage,	the	parasites	reproduce	asexually	in	the	erythrocytes	and	infect	red	blood	cells.	The	ring	stage	trophozoites	mature	into	schizonts,	which	rupture	and	release	meorozoites.	At	random,	some	parasites	also	differentiate	into	gametocytes.	Blood	stage	parasites	are	responsible	for	the	clinical	manifestation	of	the	disease	(CDC,	2016).		
	
Symptoms		 The	symptoms	seen	in	patients	can	be	categorized	as	uncomplicated	or	severe.	Symptoms	of	P.	falciparaum	occur	every	second	day	and	the	uncomplicated	symptoms	can	
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sometimes	include	a	cold	stage,	a	hot	stage,	and	finally	a	sweating	stage.	More	commonly,	patients	can	present	with	a	combination	of	fever,	chills,	sweats,	headaches,	body	aches,	nausea	and	vomiting,	and	general	malaise	(CDC,	2016).	The	severe	form	of	malaria	presents	with	manifestation	of	severe	anemia,	cerebral	malaria	(impairment	of	consciousness,	seizures,	coma	or	other	neurologic	abnormalities),	hemoglobinuria,	acute	respiratory	distress	syndrome,	acute	kidney	failure	and	more.	Manifestation	of	severe	malaria	is	considered	a	medical	emergency	and	is	strongly	advised	to	treat	aggressively	and	urgently	(CDC,	2016).	
	
Treatment		 Factors	which	determine	how	a	malaria	patient	is	treated	depends	on	the	species	of	the	infecting	parasite,	the	clinical	status	of	the	patient,	pregnancy,	drug	allergies,	the	area	where	the	infection	was	acquired,	and	any	other	accompanying	illnesses	or	conditions	all	can	effect	how	a	patient	is	treated	(CDC,	2016).	P.	falciparum	can	cause	rapidly	progressive	illness	or	death	compared	to	other	plasmodium	species.	For	treatment	of	uncomplicated	P.	
falciparum,	WHO	recommends	arteminisin-based	combination	therapy,	known	to	have	potent	activity	against	all	blood	stages	of	P.	falciparum	parasites.		ACTs	are	known	as	the	most	effective	antimalarial	medicines	available	today	for	uncomplicated	malaria	and	are	made	by	combining	two	active	ingredients	with	different	mechanisms	of	action.	There	are	5	ACTs	used	against	P.	falciparum	(WHO,	2016).		However,	the	continued	use	of	oral	ACT	is	considered	to	be	a	major	factor	contributing	to	resistance	to	arteminisin	derivatives.		Artemisinin	resistance	(ART)	is	defined	as	a	high	prevalence	of	the	delayed	parasite	clearance	phenotype	and	a	K13	resistance-associated	mutation	in	an	individual	patient	
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(Fairhurst	&	Dondorp,	2016).	There	is	still	little	known	about	artemisinin-resistant	P.	
falciparum,	however,	the	increasing	incidence	of	ACT	failures	have	posed	a	real	threat	to	malaria	treatment	and	elimination	efforts	worldwide	(Dondorp	et	al.,	2011).	
	
Malaria	Vaccine		 Efforts	to	develop	a	long	lasting	and	effective	vaccine	against	malaria	have	been	the	focus	of	many	researchers	globally.	Beginning	in	the	1930s,	the	focus	was	centralized	on	inactivated	or	killed	parasites,	which	failed	to	generate	a	protective	immune	response	(Ouattara	&	Laurens,	2015).	Beginning	with	ducklings	then	moving	to	rodents,	subsequent	vaccine	development	efforts	led	to	the	first	human	malaria	vaccine	trial	(Clyde	et.	al,	1973).	Vaccine	clinical	trials	of	the	modern	era	began	in	the	1990s,	which	utilized	sequences	from	3	P.	falciparum	blood-stage	antigens	and	the	circumsporozoite	protein	(CSP).	Studies	from	these	trials	showed	protection	in	South	America	but	none	in	Africa	(Graves	&	Gelvband,	2006).		After	35	years,	advances	such	as	parasite	cultivation	methods	and	sequencing	of	the	parasite	genome	have	given	hope	to	the	discovery	of	a	vaccine,	yet	there	are	still	unsolved	obstacles.			 While	there	are	several	categories	of	vaccines	being	developed	for	protection	in	the	pre-erythrocytic,	blood	stage	and	sexual	stages	of	the	parasite,	there	is	still	a	long	way	to	go	(Chia,	Goh,	&	Renia,	2014).	The	rationale	behind	developing	a	vaccine	to	protect	against	malaria	comes	from	previous	studies	where	naturally	acquired	immunity	to	malaria	was	shown	to	protect	against	malaria	in	an	age-dependent	and	exposure	dependent	manner	(Chia	et	al.,	2014).	Vaccine	development	is	limited	by	the	lack	of	understanding	of	mechanisms	in	a	natural	transmission	setting.	Vaccine	efforts	have	aimed	at	the	stages	of	
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sporozoite	invasion	and	liver	stage	development;	however,	long-term	immunity	has	not	yet	been	achieved	(Hill,	2011)	.	To	date,	the	RTS,	S	malaria	vaccine	is	the	candidate	furthest	advanced	through	clinical	trials	and	has	provided	some	protection	against	P.	falciparum	infection	in	humans	(Kazmin	et	al.,	2017)	and	its	efficacy	showed	only	partial	protection	with	age	specificity.	More	importantly,	vaccine	efficacy	was	undetectable	3	years	after	vaccination	(Bejon	et	al.,	2013).	Research	has	contributed	the	moderate	efficacy	to	the	lack	of	fully	understanding	the	mechanism	of	action	of	protective	immunity	(Kazmin	et	al.,	2017).			 The	pre-erythrocytic	(PE)-	stage	of	the	Plasmodium	parasite	is	an	attractive	target	for	vaccine	development.	This	stage	is	metabolically	active	but	symptomatically	silent	as	a	preparatory	phase	in	the	parasite’s	life	cycle	(Duffy	et	al.,	2012).	This	stage	is	key	for	many	reasons;	the	number	of	infected	hepatocytes	is	low	(Medica	&	Sinnis,	2005),	human	parasites	take	7	days	or	longer	to	complete	development	(Mauduit	et.	al,	2009),	and	the	infected	hepatocyte	is	able	to	present	parasite	antigens	to	immune	effector	cells	(Hoffman	et.	al,	1987).	Functional	immunoassays	using	an	in-vitro	malaria	liver-stage	infection	model	have	been	used	to	study	the	development	of	parasites	in	the	liver	for	decades	(House,	Hollingdale	et.	al,	2009).	These	models	have	helped	in	discovery	and	characterization	of	sporozoite	and	liver-stage	antigens,	help	validate	potential	malaria	vaccine	candidates	and	to	search	for	immunological	correlates	of	protection	in	humans.	These	assays	have	varied	over	time	and	between	laboratories,	but	the	underlying	ideas	remain	similar.	First,	test	serum	is	pre-incubated	with	sporozoites	from	Anopheles	female	mosquito.	Following,	the	serum/sporozoite	mixture	is	added	to	a	layer	of	human	hepatocytes	or	a	similar	substance.	Next,	incubation	is	done	to	allow	sporozoites	to	invade	the	hepatocytes.	Finally,	cells	are	
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fixed	and	stained	to	allow	for	processing	and	imaging	(Silvie,	2004).	Even	though	these	assays	were	developed	to	support	validation	and	evaluation	of	vaccine	candidates,	a	challenge	has	been	the	reliability	from	these	assays	to	correlate	with	in-vivo	protection	(Nussenzweig,	Vanderberg,	Most,	&	Orton,	1967).	Their	effects	currently	only	measure	the	effects	of	humoral	immunity	(House,	Hollingdale	et.	al,	2009).	As	discussed	previously,	a	major	difficulty	has	been	in	finding	a	vaccine	immunogen	that	elicits	a	protective	immune	response	in	humans	(Potocnjak,	Yoshida,	Nussenzweig,	&	Nussenzweig,	1980).			 Through	the	use	of	irradiated	sporozoites	the	Plasmodium	circumsporozoite	protein	was	identified	many	years	ago	to	be	a	crucial	antimalarial	vaccine	targets	(Gonzalez-Ceron	et	al.	1998).		CSP	of	all	Plasmodium	species	have	a	central	region,	variable	in	length,	with	species-specific	repeated	amino	acid	sequence	and	their	location	of	the	surface	of	infective	sporozoites	attributes	to	their	immunogenicity.	The	reaction,	which	consists	of	the	formation	of	a	thread-like	precipitate	at	the	posterior	end	of	the	sporozoites	showed	host	protection	at	high	concentrations	(Potocnjak	et	al.,	1980).	The	polymorphic	cs	gene	has	diversity	within	its	regions,	which	encode	epitopes	recognized	by	the	human	immune	system	(Egan	et	al.,	1993).	Previous	studies	also	confirm	there	is	a	relationship	between	sporozoite	motility	and	invasion	and	CSP	antibodies	function	by	blocking	sporozoite	entry	and	development	into	hepatocytes	through	a	concentration-dependent	inhibition(Stewart,	Nawrot,	Schulman,	&	Vanderberg,	1986).	Recent	experiments	in	the	Adams	Lab	revealed	immunofluorescent	stained	P.	falciparum	parasites	after	exposure	to	various	concentrations	of	anti-PfCSP	(2A10),	and	anti-PvCSP	(B483V),	and	no	antibody	control.	Visualization	with	the	culture	revealed	an	uncharacterized	appearance	and	development	as	shown	in	Figure	1	(Roth,	2014).	Although	the	“CSP	reaction”	is	a	classic	phenomenon,	
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which	sporozoite	surface	shedding	occurs	when	the	parasites	are	exposed	immune	anti-CSP	antibody	(Nussenzweig	et	al.,	1967),	this	is	not	well	characterized	for	other	antigens	and	the	post	infection	affect	has	not	been	previously	reported.		The	purpose	of	this	study	was	to	utilize	Scanning	Electron	Microscopy	to	further	visualize	the	morphology	of	sporozoite	and	analyze	the	uncharacterized	appearance.		
	Figure	1.	ILSDA		P.	falciparum	liver	stage	development	(Roth,	2014).	Representative	images	of	immunofluorescent	stained	P.	falciparum	parasites	after	exposure	to	various	concentrations	of	anti-PfCSP	(2A10),	anti-PvCSP	(B483V),	and	no	antibody	control.	PfSGS	exposure	to	higher	concentrations	(2.5	and	25	µg/mL)	of	2A10	show	a	decreased	ability	of	sporozoites	to	invade	and	develop	LS	forms.	Visualization	of	the	culture	system	show	sporozoite	interaction	with	2A10	reveal	an	uncharacterized	appearance	and	development.	Images	at	high	resolution	imaging	with	scale	bars	at	5	µm.		
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Introduction	to	Scanning	Electron	Microscopy		 A	scanning	electron	microscope	(SEM)	is	a	powerful	imaging	tool,	which	utilizes	a	focused	beam	of	electrons,	to	image	3-dimensional	topography	of	biological	specimens	at	high	magnification	(Fischer,	Hansen,	Nair,	Hoyt,	&	Dorward,	2012).	One	is	able	to	describe	the	morphology	of	structures	using	high	resolution	with	this	type	of	microscope	to	develop	valid	conclusions	about	the	characterization	of	solid	materials	(Beane,	2004).	The	microscope	was	first	developed	by	professor	Dr.	Charles	Oatlev	in	the	1950s,	and	since	has	been	used	as	a	valuable	resource	for	data	analysis.	A	SEM	requires	a	stable	power	supply,	vacuum	and	cooling	system	and	a	vibration-free	space.	To	visualize	images	with	SEM,	the	process	begins	with	an	electron	gun,	which	generates	an	electron	beam	down	a	column	onto	multiple	electromagnetic	lenses.	These	lenses	are	magnetic	coils	adjusted	to	focus	a	stream	of	electrons	that	are	then	scanned	repetitively	across	the	surface	of	a	specimen	inside	the	microscope,	releasing	a	signal	of	scattered	electrons	from	the	sample	surface.	Difference	in	surface	topology	leads	to	variations	in	the	released	signal,	which	is	captured	and	converted,	into	an	observable	image	(Argast	&	Anne,	2004).		With	an	SEM	operator,	magnification	can	also	be	controlled	for	optimal	surface	visualization.		Before	samples	can	be	analyzed	by	SEM	they	must	be	adequately	prepared	by	chemical	fixation	and	dehydration.		The	most	common	way	to	chemically	fix	samples	is	short-term	incubation	in	glutuaraldehyde	(or	glutaraldehyde-formaldehyde	mixture)	followed	by	alcohol	dehydration	(Fischer	et	al.,	2012).	To	completely	remove	all	remaining	water	a	final	treatment	is	needed.	While	critical	point	drying	(CPD)	has	been	the	most	common	and	universal	method	for	full	dehydration,	Hexamethyldisilazane	(HMDS)	has	been	used	in	replace	of	CPD	due	to	its	quickness,	ease	of	use	and	price	(Braet,	De	Zanger,	&	
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Wisse,	1997).	Depending	on	the	specimen	in	question,	the	results	between	HMDS	and	CPD	can	be	equivalent	(Nation,	1983).	After	dehydration	non-conductive	samples	like	biological	samples	must	be	treated	to	make	their	surface	conductive	for	the	electron	beam.	Sputter	coating	is	used	after	fixing	and	drying	specimens	and	helps	to	minimize	damage	and	improve	topographical	contrast.	This	improves	imaging	using	secondary	electron	detection	and	the	choice	of	metal	should	be	considered	cautiously	depending	on	the	sample	(Fischer	et	al.,	2012).	Resolution	can	reach	up	to	10	nanometers	and	the	intense	interactions,	which	occur	at	the	exterior	surface	of	specimens,	provide	great	depth	into	the	understanding	of	samples.	SEM	can	be	an	essential	tool	in	the	research	field	as	well	as	in	technological	and	industrial	applications.	 			 				
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Chapter	Two	
Materials	and	Methods	
	
Plasmodium	falciparum	sporozoites	
	 Anopheles	Stephensi	mosquitos	with	Pf	line	Navy,	NF54	were	shipped	through	World	Courier	from	the	Malaria	Institute	at	the	John	Hopkins	University	Bloomberg	School	of	Public	Health.	Mosquitos	were	cleaned	and	sporozoites	were	dissected	from	the	salivary	glands	of	the	An.	stephensi	mosquitoes	15-20	days	after	infection	and	directly	placed	into	RPMI	1640	medium.	An	aliquot	of	sporozoites	were	counted	with	a	hemocytometer	to	obtain	the	desired	amount	of	sporozoites	(10,000	per	well).			 Thirteen	mm	round	Thermanox®	coverslips	were	coated	with	Poly-L-Lysine	0.1%	solution	to	improve	adherence	of	sporozoites	to	coverslips.	The	chosen	antibodies	were	diluted	in	RPMI	1640	medium	to	obtain	the	desired	concentrations	(Table	1).	Approximately	10,000	sporozoites	per	antibody	and	concentration	were	obtained	from	the	fresh	mosquito	dissection	and	incubated	for	20	minutes	in	a	selected	well	from	the	polystyrene	24-well	plate.	After	incubation,	unbound	sporozoites	and	media	were	removed.	The	remaining	sporozoites	were	fixed	with	300	µL	Glutaraldehyde	2.5%	in	0.1M	Sodium	Cacodylate	Buffer	(SCB),	pH	7.4	for	15	minutes.	The	solution	was	then	removed	and	0.1	M	SCB	was	added	for	storage	in	4°C.			
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Table	1.	The	chosen	antibodies	and	concentrations	used	for	the	experiment	
Antibody	 Concentrations	(µg/mL)	
CSP	2A10	 25	 2.5	 0.25	
CSP	210	 25	 2.5	 0.25	
AMA1	 25	 2.5	 0.25	
CELTOS	4D1	 25	 2.5	 0.25	
CELTOS	4H12	 25	 2.5	 0.25	
	
Chemical	preparation	for	the	preservation	of	sporozoites	
	 Sodium	cacodylate	buffer	was	removed	and	0.25	mL	of	Osmium	Tetroxide	aqueous	solution	was	added	drop	wise.	After	30	minutes,	solution	was	removed	and	the	coverslips	were	washed	3	times	for	5	minutes	each	with	the	buffer.	Following,	dehydration	was	performed	with	a	graded	ethanol	series	by	subsequent	exchanges	(Table	2).	Once	all	ethanol	was	removed,	a	formulation	of	50%	Hexamethyldisilazane	and	50%	EtOH	was	added	for	twice	for	15	minutes	followed	by	0.5	mL	pure	Hexamethyldisilazane	twice	for	15	minutes.	Table	2.	Graded	ethanol	series	for	dehydration	step	in	chemical	preparation	of	specimens		
%	EtOH	 Repetitions		 Time	(minutes)	
35	 2	 1	
70	 2	 1	
95	 2	 1	
100	 3	 5			 Coverslips	were	attached	onto	aluminum	mounts	made	from	ultra-pure	aluminum,	which	had	a	double-sided	carbon	adhesive	tab	applied.	Colloidal	graphite,	carbon	particles	suspending	in	isopropanol,	was	used	to	improve	adherence	and	ensure	the	entire	coverslip	had	contact	with	carbon	to	improve	imaging.	A	sputter	coater	was	used	with	a	pump	hold	
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time	of	5	minutes,	H:M:S	of	40	seconds	and	Au:Pd	of	60:40	for	the	choice	of	metal.	Specimens	were	then	mounted	onto	an	aluminum	stub	holder	suitable	for	use	in	SEM.			
Imaging	and	data	analysis		 A	high-performance	JEOL	JSM6490	Scanning	Electron	Microscope	was	used	on	high	vacuum	mode	to	view	the	surface	and	3D	organization	of	the	sporozoites.	An	EDAX	Genesis	energy-dispersive	x-ray	analysis	system	was	used	for	elemental	analysis.	Once	sporozoites	were	placed	in	the	machine,	the	stage	was	elevated	to	16	mm	and	the	resolution	was	lowered	to	6	kV	for	optimal	imaging.	All	sporozoites	were	measured	with	the	scalar	setting	through	the	software	and	images	were	taken	with	magnification	between	7,500x	–	15,000x.	
	 	13	
	
	
	
Chapter	Three	
Results		Four	antibodies	along	with	a	positive	control	antibody	were	tested	for	the	duration	of	the	experiment:	anti-CSP2A10,	anti-PvCSP210,	AMA1,	CelTOS	4D1,	CelTOS	4H12,	CelTOS	2F12	each	at	25	µg/mL,	2.5	µg/mL	and	0.25	µg/mL.	Table	3	shows	the	antigen	along	with	their	description	and	vaccine	mechanism.	Table	3.	Description	of	the	current	malaria	vaccines	used	in	this	study	along	with	the	mechanisms	involved	
Antigen	 Description	 Vaccine	Mechanism	
CSP	 Circumsporozoite	protein	 Inhibit	sporozoite	motility;	prevent	hepatocyte	invasion	
AMA1	 Apical	membrane	antigen	1	 Target	merozoite	ligand	that	mediates	erythrocyte	and	sporozoite	invasion	(1-5)	
CelTOS	 Cell-traversal	protein	for	ookinetes	and	sporozoites	 Inhibit	sporozoite	motility;	prevent	hepatocyte	invasion	(6-7)	1-5.		(Anders	et	al.,	1998;	Deans	et	al.,	1982;	Silvie	et	al.,	2004;	Thomas,	Deans,	Mitchell,	Alderson,	&	Cohen,	1984;	Waters	et	al.,	1990).	6-7.	(Bergmann-Leitner,	Legler,	Savranskaya,	Ockenhouse,	&	Angov,	2011;	Bergmann-Leitner	et	al.,	2010)			 Two	sets	of	50	sporozoites	for	each	concentration	of	each	antibody	were	imaged	to	accumulate	a	total	of	100	sporozoites	analyzed.	The	sporozoites	were	classified	as	normal	(smooth,	elongated)	or	with	different	abnormal	appearances,	which	were	broken	down	according	to	the	descriptions	in	Table	4.			
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			Table	4.	Definitions	of	the	abnormal	appearances	seen	through	Scanning	Electron	Microscopy	
Type		 Description	Rugged	 Wrinkled,	jagged	sporozoite	surface	Damaged	 Physical	harm	affecting	sporozoite	shape	Loose	surface	membrane	 Sporozoite	surface	membrane	is	thinner	and	weaker,	causing	disattachment	Surface	Membrane	Tear	 Tear	in	the	surface	membrane			 Sporozoites	incubated	with	anti-PvCSP210,	reactive	the	210	variant	of	P.	vivax	CSP,	was	used	as	the	negative	antibody	control	in	addition	to	a	no	antibody	control.	There	were	a	total	of	91	sporozoites	with	a	normal	appearance	of	smooth	and	elongated	in	the	negative	control	sample.	9	sporozoites	had	some	minor	damage	or	a	surface	membrane	tear.	This	was	compared	to	the	positive	control	anti-PvCSP210,	along	with	the	other	antibodies	chosen	for	this	study.			 Anti-PvCSP210	and	the	sporozoites	with	no	antibody	were	compared	as	seen	by	Figure	1	and	Figure	2.	Figure	1	shows	the	number	of	anti-PvCSP210	with	a	normal	appearance	at	25	µg/mL,	2.5	µg/mL	and	0.25	µg/mL	were	80,	82,	and	87	sporozoites	respectively.	Figure	2	compares	the	subsections	of	abnormal	differences	between	anti-PfCSP	MAB2A10	and	no	antibody.	For	the	differences	within	the	uncharacterized	sporozoites,	all	types	appeared	within	every	concentration	of	antibody.	
	 	15	
	Figure	2.	100	P.	Falciparum	sporozoites	with	no	antibody	(as	the	negative	control)	were	compared	with	100	anti-	CSP	210	induced	sporozoites	(as	the	positive	control)	at	25	µg/mL,	2.5	µg/mL	and	0.25	µg/mL	
	
	Figure	3.	Comparison	between	the	amount	of	uncharacteristic	findings	of	P.	falciparum	sporozoites	with	no	antibody	and	anti-	CSP	210	induced	sporozoites	(as	the	positive	control)	at	25	µg/mL,	2.5	µg/mL	and	0.25	µg/mL			 Anti-PfCSP	MAB2A10,	reactive	with	all	P.	falciparum	CSP	was	then	compared	to	the	sporozoites	with	no	antibody	as	seen	in	Figure	4.	This	shows	the	number	of	sporozoites	exposed	to		anti-PfCSP	MAB2A10	with	a	normal	appearance	at	25	µg/mL,	2.5	µg/mL	and	
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0.25	µg/mL	were	5,	13	and	61	sporozoites,	respectively.	For	the	differences	within	the	uncharacterized	sporozoites,	all	types	appeared	other	than	anti-PfCSP	MAB2A10	2.5	µg/mL	did	not	have	any	sporozoites	with	a	surface	membrane	tear.	
	Figure	4.	100	P.	falciparum	sporozoites	with	no	antibody	(as	the	negative	control)	were	compared	with	100	anti-	CSP	2A10	induced	sporozoites	at	25	µg/mL,	2.5	µg/mL	and	0.25	µg/mL		
	Figure	5.	Comparison	between	the	amount	of	uncharacteristic	findings	of	P.	falciparum	sporozoites	with	no	antibody	and	anti-	CSP	2A10	induced	sporozoites	at	25	µg/mL,	2.5	µg/mL	and	0.25	µg/mL		
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	 Figure	6	displays	the	comparison	between	Pf	with	no	antibody	and	Apical	Membrane	Antigen	1	(AMA1).	This	graph	represents	the	number	of	anti-AMA1	with	a	normal	appearance	at	25	µg/mL,	2.5	µg/mL	and	0.25	µg/mL	were	at	64,	70,	and	76	sporozoites,	respectively.	
	Figure	6.	100	P.	falciparum	sporozoites	with	no	antibody	(as	the	negative	control)	were	compared	with	100	anti-	AMA1	induced	sporozoites	at	25	µg/mL,	2.5	µg/mL	and	0.25	µg/mL			 The	comparison	of	the	abnormal	morphological	differences	between	Pf	with	no	antibody	and	AMA1	characterizes	the	AMA1	25	µg/mL	and	2.5	µg/mL	to	have	a	rugged	appearance,	only	AMA	25	µg/mL	to	have	a	loose	a	surface	membrane	and	all	concentrations	besides	the	AMA1	25	µg/mL	to	have	sporozoites	with	a	surface	membrane	tear	(Figure	7).		
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	Figure	7.	Comparison	between	the	amount	of	uncharacteristic	findings	of	P.	falciparum	sporozoites	with	no	antibody	and	anti-	AMA1	induced	sporozoites	at	25	µg/mL,	2.5	µg/mL	and	0.25	µg/mL			 The	third	type	of	antibody	evaluated	for	reactivity	against	sporozoites	was	developed	against	recombinant	protein	of	cell-traversal	proteins	for	ookinetes	and	sporozoites	(CelTOS),	Figure	8	shows	the	comparison	between	Pf	with	no	antibody	and	CelTOS	serum	IgG	4D1.	Here,	it	is	indicated	there	were	75,	56	and	89	normal	appearing	sporozoites	for	25	µg/mL,	2.5	µg/mL	and	0.25	µg/mL	concentrations	respectively.			
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	Figure	8.	100	P.	falciparum	sporozoites	with	no	antibody	(as	the	negative	control)	were	compared	with	100	anti-	CelTOS	4D1	induced	sporozoites	at	25	µg/mL,	2.5	µg/mL	and	0.25	µg/mL		Figure	9	presents	the	comparison	of	abnormal	morphological	differences	between	Pf	with	no	antibody	and	CelTOS	4D1	at	each	concentration.	All	concentrations	had	a	damaged	appearance	or	surface	membrane	tear	and	4D1	2.5	µg/mL	was	the	only	antibody	to	have	sporozoites	with	a	loose	surface	membrane.			
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	Figure	9.	Comparison	between	the	amount	of	uncharacteristic	findings	of	P.	falciparum	sporozoites	with	no	antibody	and	anti-CelTOS	4D1	induced	sporozoites	at	25	µg/mL,	2.5	µg/mL	and	0.25	µg/mL			 The	last	antibody-induced	treatments	of	sporozoites	analyzed	sporozoites	with	antibody	to	CelTOS	4H12.	Figure	10	shows	the	amount	sporozoites	with	a	normal	morphology	as	42	sporozoites	for	25	µg/mL,	45	sporozoites	for	2.5	µg/mL	and	70	sporozoites	for	0.25	µg/mL.			
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	Figure	10.	100	P.	falciparum	sporozoites	with	no	antibody	(as	the	negative	control)	were	compared	with	100	anti-	CelTOS	4H12	induced	sporozoites	at	25	µg/mL,	2.5	µg/mL	and	0.25	µg/mL		For	the	comparison	of	the	abnormal	morphological	differences,	Figure	11	shows	that	sporozoites	at	all	concentrations	had	the	damaged	appearance	or	surface	membrane.	4H12	25	µg/mL	and	2.5	µg/mL	each	presented	with	sporozoites	with	a	loose	surface	membrane.	
	Figure	11.	Comparison	between	the	amount	of	uncharacteristic	findings	of	P.	falciparum	sporozoites	with	no	antibody	and	anti-CelTOS	4H12	induced	sporozoites	at	25	µg/mL,	2.5	µg/mL	and	0.25	µg/mL		
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The	length	and	width	of	each	sporozoite	was	taken	as	well	to	analyze	the	no	antibody	sporozoites	with	the	antibody-induced	sporozoites	(Table	5).		Table	5.	Length	(um)	average	and	width	(um)	average	of	100	sporozoites	for	each	antibody	and	concentration	
	
	Figure	12.	Scanning	Electron	Microscopy	image	of	a	smooth,	elongated	sporozoite.	The	magnification	is	x9,500	to	have	an	image	of	the	whole	sporozoite	with	a	kV	of	6	and	spot	size	of	30.	
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	Figure	13.	Scanning	Electron	Microscopy	image	of	a	damaged	sporozoite.	The	magnification	is	x11,000	to	have	an	image	of	the	whole	sporozoite	with	a	kV	of	6	and	spot	size	of	30.				
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	Figure	14.	Scanning	Electron	Microscopy	image	of	a	sporozoite	with	a	loose	surface	membrane.	The	magnification	is	x9,000	to	have	an	image	of	the	whole	sporozoite	with	a	kV	of	6	and	spot	size	of	30.				
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	Figure	15.	Scanning	Electron	Microscopy	image	of	a	sporozoite	with	a	rugged	surface.	The	magnification	is	x13,000	to	have	an	image	of	the	whole	sporozoite	with	a	kV	of	6	and	spot	size	of	30.			
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	Figure	16.	Scanning	Electron	Microscopy	image	of	a	sporozoite	with	a	surface	membrane	tear.	The	magnification	is	x12,000	to	have	an	image	of	the	whole	sporozoite	with	a	kV	of	6	and	spot	size	of	30
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Chapter	Four	
Discussion			 The	images	produced	by	SEM	do	reveal	uncharacterized	appearances	and	development	in	antibody-induced	sporozoites	consistent	with	the	findings	in	previous	studies	by	the	Adams	Lab.	The	abnormalities	were	most	prevalent	in	the	highest	concentration	of	MAB2A10,	25	µg/mL.	While	there	appeared	to	be	no	correlation	between	the	subsections	of	the	abnormalities,	the	three	types	did	appear	in	each	of	the	concentrations.	These	uncharacterized	appearances	appear	to	correlate	with	the	impairment	of	hepatocyte	invasion.	The	CSP	monoclonal	antibody	used	has	been	shown	to	abolish	or	diminish	sporozoite	infectivity	(Hollingdale	et.	al	1984)	and	with	this	study,	the	morphological	changes	to	the	sporozoite	can	provide	insight	into	the	mechanism	in	which	it	occurs.	When	compared	to	anti-PvCSP210,	which	was	the	positive	antibody	control,	anti-PfCSP	had	more	sporozoites	with	uncharacterized	appearance.		 Apical	Membrane	Antigen	1	(AMA1),	is	a	microneme	protein	associated	with	merozoite	invasion	(Silvie	et.	al.,	2004).	AMA1	is	mostly	sequestered	inside	the	sporozoite,	however,	upon	exocytosis	it	surfaces	to	the	external	part	of	the	sporozoite	suggesting	its	importance	to	the	parasite	invasion.	Many	studies	have	further	investigated	the	proteolytic	function	of	AMA1	to	confer	a	valuable	strategy	in	preventing	hepatocyte	invasion.	Here,	we	can	see	that	the	anti-AMA1	antibody	does	impact	the	morphology	of	sporozoites	with	as	
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little	as	20-minute	incubation	time.	While	it	is	not	as	apparent	in	the	lower	concentrations,	the	antibody	itself	does	start	appear	to	damage	to	external	features	of	sporozoite.	Even	though	this	microneme	protein	is	targeted	due	to	the	impact	on	the	erythrocytic	stages,	the	morphology	changes	shown	do	provide	further	insight	in	the	possible	inhibitory	effects,	which	can	come	from	inducing	the	protein	in	early	developmental	stages.			 With	the	anti-CelTOS	antibodies,	there	were	not	as	many	sporozoites	with	uncharacterized	appearances.	These	antibodies	are	which	are	used	to	block	hepatocyte	invasion	and	inhibit	sporozoite	mobility,	are	unique	because	they	achieve	nearly	universal	inner	leaflet	cellular	activity	(Jimah	et.	al.,	2016).	Therefore,	to	have	mild	changes	to	the	external	features	of	the	sporozoites	correlates	with	this	finding.	Further	studies	could	be	useful	to	be	able	to	test	and	analyze	other	potential	vaccine	targets	and	their	morphological	effects	on	sporozoites.
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